Trimebutine 5.8% / Ruscogenins 0.5% ointment

Objective: To compare the clinical efficacy of traditional Chinese medicine with trimebutine maleate in the treatment of diarrheal irritable bowel syndrome (liver stagnation and spleen deficiency type). Methods: The computer searched CNKI, Wangfang Data, VIP, Chinese Medical Database, web of science, PubMed, and The Cochrane Library for clinical randomized controlled trials of traditional Chinese medicine versus trimebutine maleate in the treatment of IBS-D, and analyzed the data with RevMan and Stata software. Results: A total of 20 RCTs with a total of 2,496 subjects were included, with 1,270 in the treatment group and 1,226 in the control group. The results of the meta-analysis revealed that traditional Chinese medicine outperforms trimebutine in terms of total effective rate of treatment, abdominal pain score, diarrhea score, bloating score, defecation satisfaction score, defecation frequency score, stool trait score, irritability, adverse reactions, and recurrence rate, and the difference is statistically significant (P<0.05). Conclusion: Traditional Chinese medicine has definite efficacy in the treatment of IBS-D, and the effect is superior to trimebutine maleate, making it suitable for clinical promotion and application.

Abstract licence: CC BY

BACKGROUND: Abemaciclib-induced diarrhea (AID) impairs quality of life (QOL) and treatment adherence in patients with breast cancer. Supportive treatment with loperamide is associated with constipation. We hypothesized that probiotics and trimebutine maleate (TM) would decrease the frequency of AID without causing constipation. METHODS: Hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer patients were randomized into the probiotic Bifidobacterium (A) or probiotic Bifidobacterium and TM (B) groups. Endocrine therapy, Abemaciclib and probiotic Bifidobacterium three times a day for 28 days, was administered to both arms. Arm B was treated with TM upon the onset of diarrhea. The primary endpoint was the percentage of patients who experienced grade ≥2 diarrhea. The secondary endpoints were safety, frequency, and duration of all-grade diarrhea; frequency of emesis and constipation; usage of loperamide; and health-related QOL/patient-reported outcome during the study. We evaluated whether the primary endpoint of each arm exceeded the predetermined threshold. RESULTS: Fifty-one patients completed treatment. Grade 2 diarrhea occurred in 52% and 50% of patients in Arm A and Arm B, respectively. One patient experienced grade 3 diarrhea in each arm. The median duration of grade2 diarrhea was 2 and 2.5day, and only one patient required dose reduction. Grade ≥2 constipation was observed in 4% of Arm A and 3.6% of Arm B. CONCLUSIONS: Probiotic Bifidobacterium or the combination of probiotic Bifidobacterium with TM did not decrease the incidence of grade 2 or greater diarrhea compared with historical control, although the grade 3 or greater diarrhea was reduced. CLINICAL TRIAL REGISTRATION: jRCT (Japan registry of clinical trials). jRCTs031190154.

Abstract licence: CC BY-NC-ND

Background/Aims: Drugs that stabilize intestinal motility may improve the efficacy of nonabsorbable antibiotics, such as rifaximin, against small intestinal bacterial overgrowth (SIBO). We compared the efficacy of rifaximin alone with that of its combination with trimebutine maleate against SIBO. Methods: ) glucose breath test (GBT). Patients were randomized into 2 groups in a 1:1 ratio, namely rifaximin (1200 mg/day) + trimebutine maleate (600 mg/day) group and rifaximin + placebo group, for 2 weeks. Patients completed a symptom questionnaire and underwent a GBT at baseline and at 1 month after treatment withdrawal. The primary outcome was SIBO eradication. The secondary outcomes included changes in the concentrations of exhaled gases, symptoms, and presence of adverse events. Results: concentration were conspicuously decreased in the combined group after treatment. The combined group exhibited substantial relief of bloating. The adverse events were similar in the 2 groups. Conclusion: .

Abstract licence: CC BY-NC

Trimebutine, a selective antispasmodic and gastrointestinal motility modulator, was evaluated for symptom control in functional dyspepsia and overlapping functional gastrointestinal disorders. A multicenter, prospective observational study was conducted in four centers in Sofia, Bulgaria, enrolling 161 patients aged 24–75 years diagnosed according to the Rome IV criteria. All patients received trimebutine maleate 300 mg once daily for four weeks, with symptom severity assessed on a 0–5 self-reported scale. At study completion, more than 90% of patients demonstrated symptomatic improvement across upper and lower gastrointestinal symptoms. No statistically significant difference was observed between trimebutine monotherapy and combined proton pump inhibitor therapy in alleviating upper gastrointestinal symptoms at week four. The findings suggest that trimebutine at a 300 mg daily dose is effective in reducing functional gastrointestinal symptoms over a four-week period. These results support further investigation through randomized controlled trials to confirm efficacy and optimize combination strategies.

Abstract licence: CC BY

Background and Objectives: Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders; it has a great impact on patient quality of life and is difficult to treat satisfactorily. This study evaluates the efficacy and safety of trimebutine maleate (TM) in patients with FD. Materials and Methods: A multicenter, randomized, double-blind, placebo controlled, prospective study was conducted, including 211 patients with FD. Participants were randomized to receive TM 300 mg twice per day (BID, 108 patients) or placebo BID (103 patients) for 4 weeks. The Glasgow Dyspepsia Severity Score (GDSS) was used to evaluate the relief of dyspepsia symptoms. Moreover, as a pilot secondary endpoint, a substudy (eight participants on TM and eight on placebo) was conducted in to evaluate gastric emptying (GE), estimated using a 99mTc-Tin Colloid Semi Solid Meal Scintigraphy test. Results: Of the 211 patients enrolled, 185 (87.7%) (97 (52.4%) in the TM group and 88 (47.6%) in the placebo group) completed the study and were analyzed. The groups did not differ in their demographic and medical history data. Regarding symptom relief, being the primary endpoint, a statistically significant reduction in GDSS for the TM group was revealed between the first (2-week) and final (4-week) visit (p-value = 0.02). The 99 mTc-Tin Colloid Semi Solid Meal Scintigraphy testing showed that TM significantly accelerated GE obtained at 50 min (median emptying 75.5% in the TM group vs. 66.6% in the placebo group, p = 0.036). Adverse effects of low to moderate severity were reported in 12.3% of the patients on TM. Conclusion: TM monotherapy appears to be an effective and safe approach to treating FD, although the findings presented here warrant further confirmation.

Abstract licence: CC BY

Alkaline burns to the cornea lead to loss of corneal transparency, which is essential for normal vision. We used a rat corneal alkaline burn model to investigate the effect of ophthalmic trimebutine solution on healing wounds caused by alkaline burns. Trimebutine, an inhibitor of the high-mobility group box 1-receptor for advanced glycation end products, when topically applied to the burned cornea, suppressed macrophage infiltration in the early phase and neutrophil infiltration in the late phase at the wound site. It also inhibited neovascularization and myofibroblast development in the late phase. Furthermore, trimebutine effectively inhibited interleukin-1β expression in the injured cornea. It reduced scar formation by decreasing the expression of type III collagen. These findings suggest that trimebutine may represent a novel therapeutic strategy for corneal wounds, not only through its anti-inflammatory effects but also by preventing neovascularization.

Abstract licence: CC BY